ADMA Biologics (NASDAQ:ADMA) Hits New 52-Week High – Time to Buy?

ADMA Biologics, Inc. (NASDAQ:ADMA) shares reached a new 52-week high on Monday . The stock traded as high as $25.67 and last traded at $24.48, with a volume of 2041269 shares traded. The stock had previously closed at $21.86.

Analyst Ratings Changes

Separately, Cantor Fitzgerald restated an “overweight” rating and issued a $25.00 price objective on shares of ADMA Biologics in a research report on Tuesday, March 4th.

ADMA Biologics Stock Performance

The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The stock has a 50-day moving average price of $18.80 and a 200-day moving average price of $18.27. The company has a market capitalization of $5.63 billion, a price-to-earnings ratio of 85.01 and a beta of 0.53.

Institutional Investors Weigh In On ADMA Biologics

A number of hedge funds and other institutional investors have recently made changes to their positions in ADMA. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its holdings in shares of ADMA Biologics by 1.3% during the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 50,466 shares of the biotechnology company’s stock worth $865,000 after buying an additional 645 shares in the last quarter. Oregon Public Employees Retirement Fund boosted its stake in shares of ADMA Biologics by 1.3% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 55,600 shares of the biotechnology company’s stock valued at $954,000 after purchasing an additional 700 shares in the last quarter. Summit Investment Advisors Inc. increased its stake in shares of ADMA Biologics by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 23,560 shares of the biotechnology company’s stock valued at $404,000 after buying an additional 746 shares during the period. Mutual of America Capital Management LLC raised its holdings in ADMA Biologics by 2.1% in the 4th quarter. Mutual of America Capital Management LLC now owns 35,807 shares of the biotechnology company’s stock valued at $614,000 after buying an additional 751 shares during the last quarter. Finally, Maryland State Retirement & Pension System raised its stake in shares of ADMA Biologics by 1.1% during the fourth quarter. Maryland State Retirement & Pension System now owns 79,607 shares of the biotechnology company’s stock valued at $1,365,000 after acquiring an additional 897 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.